[呼吸道合胞病毒疫苗的前景]

Ann Sclavo. 1980 Jan-Feb;22(1):40-1.

The latest vaccines for Respiratory Syncytial Virus (RSV) are reviewed. A ts-1 variant is being studied in the attempt to complete the attenuation of the vaccine strain. Further investigations of live RSV vaccine administered parenterally indicate that a target population over 6 months of age could benefit soon of this preparation.

对呼吸道合胞病毒（RSV）的最新疫苗进行了综述。正在研究一种ts-1变体，以试图完成疫苗株的减毒。对经肠胃外给药的活RSV疫苗的进一步研究表明，6个月以上的目标人群可能很快从这种制剂中受益。